165 related articles for article (PubMed ID: 38349407)
1. FDA-approved disulfiram as a novel treatment for aggressive leukemia.
Karsa M; Xiao L; Ronca E; Bongers A; Spurling D; Karsa A; Cantilena S; Mariana A; Failes TW; Arndt GM; Cheung LC; Kotecha RS; Sutton R; Lock RB; Williams O; de Boer J; Haber M; Norris MD; Henderson MJ; Somers K
J Mol Med (Berl); 2024 Apr; 102(4):507-519. PubMed ID: 38349407
[TBL] [Abstract][Full Text] [Related]
2. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.
Huang H; Liao Y; Liu N; Hua X; Cai J; Yang C; Long H; Zhao C; Chen X; Lan X; Zang D; Wu J; Li X; Shi X; Wang X; Liu J
Oncotarget; 2016 Jan; 7(3):2796-808. PubMed ID: 26625200
[TBL] [Abstract][Full Text] [Related]
3. Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin.
Karsa M; Kosciolek A; Bongers A; Mariana A; Failes T; Gifford AJ; Kees UR; Cheung LC; Kotecha RS; Arndt GM; Haber M; Norris MD; Sutton R; Lock RB; Henderson MJ; Somers K
Br J Cancer; 2021 Jul; 125(1):55-64. PubMed ID: 33837299
[TBL] [Abstract][Full Text] [Related]
4. Alcohol-abuse drug disulfiram targets pediatric glioma via MLL degradation.
Meier S; Cantilena S; Niklison Chirou MV; Anderson J; Hargrave D; Salomoni P; de Boer J; Michod D
Cell Death Dis; 2021 Aug; 12(8):785. PubMed ID: 34381018
[TBL] [Abstract][Full Text] [Related]
5. Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.
Xu B; Wang S; Li R; Chen K; He L; Deng M; Kannappan V; Zha J; Dong H; Wang W
Cell Death Dis; 2017 May; 8(5):e2797. PubMed ID: 28518151
[TBL] [Abstract][Full Text] [Related]
6. Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies.
Conticello C; Martinetti D; Adamo L; Buccheri S; Giuffrida R; Parrinello N; Lombardo L; Anastasi G; Amato G; Cavalli M; Chiarenza A; De Maria R; Giustolisi R; Gulisano M; Di Raimondo F
Int J Cancer; 2012 Nov; 131(9):2197-203. PubMed ID: 22322883
[TBL] [Abstract][Full Text] [Related]
7. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
8. Disulfiram/copper causes ROS levels alteration, cell cycle inhibition, and apoptosis in acute myeloid leukaemia cell lines with modulation in the expression of related genes.
Hassani S; Ghaffari P; Chahardouli B; Alimoghaddam K; Ghavamzadeh A; Alizadeh S; Ghaffari SH
Biomed Pharmacother; 2018 Mar; 99():561-569. PubMed ID: 29902866
[TBL] [Abstract][Full Text] [Related]
9. The disulfiram/copper complex induces apoptosis and inhibits tumour growth in human osteosarcoma by activating the ROS/JNK signalling pathway.
Guo W; Zhang X; Lin L; Wang H; He E; Wang G; Zhao Q
J Biochem; 2021 Oct; 170(2):275-287. PubMed ID: 33792698
[TBL] [Abstract][Full Text] [Related]
10. Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition.
Zha J; Chen F; Dong H; Shi P; Yao Y; Zhang Y; Li R; Wang S; Li P; Wang W; Xu B
J Transl Med; 2014 Jun; 12():163. PubMed ID: 24915933
[TBL] [Abstract][Full Text] [Related]
11. Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition.
Papaioannou M; Mylonas I; Kast RE; Brüning A
Oncoscience; 2014; 1(1):21-9. PubMed ID: 25593981
[TBL] [Abstract][Full Text] [Related]
12. Blockade of ALDH in Cisplatin-Resistant Ovarian Cancer Stem Cells In Vitro Synergistically Enhances Chemotherapy-Induced Cell Death.
Guo F; Yang Z; Sehouli J; Kaufmann AM
Curr Oncol; 2022 Apr; 29(4):2808-2822. PubMed ID: 35448203
[TBL] [Abstract][Full Text] [Related]
13. Menin‑MLL inhibitors induce ferroptosis and enhance the anti‑proliferative activity of auranofin in several types of cancer cells.
Kato I; Kasukabe T; Kumakura S
Int J Oncol; 2020 Oct; 57(4):1057-1071. PubMed ID: 32945449
[TBL] [Abstract][Full Text] [Related]
14. Curcumin enhances the cytogenotoxic effect of etoposide in leukemia cells through induction of reactive oxygen species.
Papież MA; Krzyściak W; Szade K; Bukowska-Straková K; Kozakowska M; Hajduk K; Bystrowska B; Dulak J; Jozkowicz A
Drug Des Devel Ther; 2016; 10():557-70. PubMed ID: 26893544
[TBL] [Abstract][Full Text] [Related]
15. Effective elimination of adult B-lineage acute lymphoblastic leukemia by disulfiram/copper complex in vitro and in vivo in patient-derived xenograft models.
Deng M; Jiang Z; Li Y; Zhou Y; Li J; Wang X; Yao Y; Wang W; Li P; Xu B
Oncotarget; 2016 Dec; 7(50):82200-82212. PubMed ID: 27203215
[TBL] [Abstract][Full Text] [Related]
16. Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL.
Chen L; Ren A; Zhao Y; Chen H; Wu Q; Zheng M; Zhang Z; Zhang T; Zhong W; Lin J; Zhu H
J Hematol Oncol; 2023 Nov; 16(1):113. PubMed ID: 37993905
[TBL] [Abstract][Full Text] [Related]
17. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
18. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia.
Fiskus W; Saba N; Shen M; Ghias M; Liu J; Gupta SD; Chauhan L; Rao R; Gunewardena S; Schorno K; Austin CP; Maddocks K; Byrd J; Melnick A; Huang P; Wiestner A; Bhalla KN
Cancer Res; 2014 May; 74(9):2520-32. PubMed ID: 24599128
[TBL] [Abstract][Full Text] [Related]
19. Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.
Yang Z; Guo F; Albers AE; Sehouli J; Kaufmann AM
Biomed Pharmacother; 2019 May; 113():108727. PubMed ID: 30870721
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
